|
|
| Introduction The Hepatitis C market was worth $2.3 billion in 2007, declining at a CAGR of -2.8% from 2004-2007. Despite this recent slump, Datamonitor forecasts sales to grow to $4.5 billion by 2017, driven primarily by the launch of the new protease inhibitors. The US and EU will remain the largest markets, generating $1.9 billion and $1.7 billion respectively in 2017. Reasons to Purchase
|
Related Markets
Hepatitis Reports
- Chinese Markets for Hepatitis Drugs
- Liver Disease Treatments: The Global Market
- Hepatitis Market to 2017 - Strong Hepatitis-C Pipeline, Large Number of Strategic Consolidations and Cost Effective Treatments will Drive the Market
- Hepatitis B Vaccines - Pipeline Assessment and Market Forecasts to 2018
- Hepatitis C Global Clinical Trials Review, H2, 2011
